• First-in-class peptidomimetic with distinct MoA activating trophic signaling pathways to protect and prevent damage to the optic nerve and retina
  • Potential to be disease modifying in lead indications such as glaucoma, geographic atrophy, acute optic neuritis (AON) and other optic neuropathies
  • Proof of concept (PoC) clinical trial in progress for AON with results due 2H23
  • Agreement supports Oculis’s mission to become a global ophthalmology leader bringing breakthrough innovations to the top three segments of the market: retina, dry eye and glaucoma
  • Deal validates Accure’s strategy as a translational R&D engine in neuroscience

About the author.


No Comments. Leave a comment  


您的电子邮箱地址不会被公开。 必填项已用 * 标注